Global Vaccines Market by Technology (Recombinant, Toxoid, Conjugate, RNA), Type (Monovalent, Multivalent), Disease (Pneumococcal, Influenza, DTP, HPV, MMR, COVID-19), Route of Administration (IM, SC, Oral), End user (Pediatric, Adult) & Region - Forecast to 2028

The global vaccines market size is projected to reach USD 93.8 billion by 2028 from USD 77.6 billion in 2023, at a CAGR of 3.9% during the forecast period. Factors such as high incidence of contagious diseases, innovation in vaccine technology, governmental support & substantial funding for vaccine development, growing vaccination initiatives and strong focus on investing and launching innovative vaccines.

The conjugate vaccines segment held the dominant share in the vaccines market

Based on technology, the global vaccines market is segmented into inactivated & subunit vaccines, live attenuated vaccines, toxoid vaccines, viral vector vaccines, recombinant vaccines and conjugate vaccines. The conjugate vaccines segment  is anticipated to grow at significant CAGR. Growing governmental support coupled with investment by companies in the field of conjugate vaccine development, increasing collaboration between public and private sectors are likely to have positive impact on the growth of the market. 

Pneumococcal segment accounted for the largest share of the disease indication segment in 2022.

Based on disease indication, the vaccines market is segmented into, combination vaccines, HPV, meningococcal disease, herpes zoster, rotavirus, MMR, pneumococcal disease, influenza, varicella, hepatitis, DTP, polio, and other disease indications. In 2022, the pneumococcal segment accounted for the largest share of the vaccines market. The segment held the dominant share in the market owing to various factors such increased pneumococcal disease cases, with a rising government investment in vaccination programs.

Asia Pacific region is likely to grow at a faster pace in the vaccines market.

The vaccines market region is segmented into North America, Europe, Asia Pacific, Latin America, Middle East and the Africa. Asia Pacific region is anticipated to grow at a significant CAGR during the forecast period. The growth of the region is majorly driven by companies that are upping their investments in Asia-Pacific region, benefiting from increased government support for vaccine development, rising healthcare expenditure in Asian countries, emergence & re-emergence of contagious disease and rising disposable income. 

The primary interviews conducted for this report can be categorized as follows:

•    By Respondent: Supply Side- 80%, and Demand Side - 20%
•    By Designation (Supply Side): Managers - 45%, CXOs & Directors - 30%, Executives- 25%
•    By Region: North America -40%, Europe -25%, Asia-Pacific -20%, Latin America -10%, Middle East-4%  and Africa -1%

List of Companies Profiled in the Report:

•    GSK plc (UK)
•    Merck & Co., Inc. (US)
•    Pfizer, Inc. (US)
•    Sanofi (France)
•    CSL (Australia)
•    Emergent (US)
•    Johnson & Johnson Services Inc. (US)
•    AstraZeneca (UK)
•    Serum Institute of India Pvt. Ltd. (India)
•    Bavarian Nordic (Denmark)
•    Mitsubishi Tanabe Pharma Corporation (Japan)
•    Daiichi Sankyo Company, Limited (Japan)
•    Panacea Biotec (India)
•    Biological E. Limited (India)
•    Bharat Biotech (India)
•    Novavax (US)
•    Inovio Pharmaceuticals (US)
•    Sinovac (China)
•    Incepta Pharmaceuticals (Bangladesh)
•    Valneva SE (France), 
•    VBI Vaccines Inc. (US)
•    Bio Farma (Indonesia)
•    FSUE NPO Microgen (Russia) 
•    ZHI FEI Biological (China)
•    Indian Immunologicals Ltd (India)

Research Coverage:

This report provides a detailed picture of the vaccines market. It aims at estimating the size and future growth potential of the market across different segments such as the technology, type, disease indication, route of administration, end-user and region. The report also includes an in-depth competitive analysis of the key market players along with their company profiles recent developments and key market strategies.

Key Benefits of Buying the Report:

The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall vaccines market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.

The report provides insights on the following: 

• Analysis of key drivers (strong emphasis on investment and launch of novel vaccines, rising prevalence of infectious disease, expanding immunization programs, advancements in vaccine technology and robust government support & funding for the development of vaccines), restraints (High development cost, patent expiry ), opportunities (Increased focus on therapeutic vaccines, robust & strong pipeline) and challenges (stringnent regulatory processes, vaccine supply shortage, frequent product recall) are influencing the growth of clinical trial supplies market.
• Product Development/Innovation: Detailed insights on newly launched products of the vaccines market.
• Market Development: Comprehensive information about lucrative markets – the report analyses the vaccines market across varied regions. 
• Market Diversification: Exhaustive information about new services, untapped geographies, recent developments, and investments in the vaccines market. 
• Pipeline Analysis: Comprehensive information about products under clinical trials. 
• Competitive Assessment: In-depth assessment of market shares, growth strategies, and service offerings of leading players include GSK plc (UK), Merck & Co., Inc. (US), Pfizer, Inc. (US), Sanofi (France), CSL (Australia), Emergent (US), Johnson & Johnson Services Inc. (US), AstraZeneca (UK), Serum Institute of India Pvt. Ltd. (India), Bavarian Nordic (Denmark).